Literature DB >> 24578940

A case of metastatic prostate adenocarcinoma to an inguinal lymph node.

Mitsuru Komeya1, Tamami Sahoda1, Shinpei Sugiura1, Takuto Sawada1, Kazuo Kitami1.   

Abstract

A 47-year-old man presented with dysuria. The prostate-specific antigen level was 65.5 ng/mL. Retropubic radical prostatectomy and regional lymphadenectomy revealed moderately differentiated adenocarcinoma (Gleason score 3 + 4 = 7, pT2N0). Postoperative adjuvant hormonal therapy was started immediately. Three years later, hormonal therapy was changed to anti-androgen monotherapy. Monotherapy was continued for eight years and then discontinued because the PSA level was maintained at <0.04 ng/mL. However, biochemical recurrence occurred 12 months after adjuvant hormonal therapy was discontinued. A computed tomography scan showed left inguinal lymphadenopathy. Biopsy of the swollen inguinal lymph node revealed metastatic prostate cancer. We report a rare case of metastatic prostate adenocarcinoma only to the inguinal lymph nodes.

Entities:  

Keywords:  inguinal lymphadenopathy; postoperative recurrence; prostate adenocarcinoma

Year:  2012        PMID: 24578940      PMCID: PMC3921775          DOI: 10.5173/ceju.2012.02.art11

Source DB:  PubMed          Journal:  Cent European J Urol        ISSN: 2080-4806


INTRODUCTION

Prostate adenocarcinoma is the most common cancer in males and the second leading cause of cancer death [1]. Approximately one-half of patients with prostate cancer have metastatic lesions at presentation. Bones and regional lymph nodes are the most common sites of metastasis. However, metastasis to inguinal lymph nodes in the absence of pelvic lymphadenopathy or other metastases is uncommon. Prostate cancer spreads via the lymphatics from the obturator lymph nodes to the presacral, lateral sacral, internal and external iliac, and inguinal lymph nodes. Inguinal lymphadenopathy is also a manifestation of carcinoma, metastatic disease, lymphoma, and leukemia. In such cases, biopsy of the lymphadenopathy can be an effective diagnostic tool. We report a rare case of metastatic prostate adenocarcinoma only to the inguinal lymph nodes.

CASE REPORT

A 47-year-old man presented with dysuria. Digital rectal examination revealed a nodule in the left lobe of the prostate. The prostate-specific antigen (PSA) level was 65.5 ng/mL. Transrectal biopsy of the prostate revealed adenocarcinoma. A computed tomography (CT) scan, magnetic resonance imaging, and bone scan showed no metastasis. After two months of neoadjuvant hormonal therapy (leuproreline and bicalutamide), retropubic radical prostatectomy and obturator lymph node dissection were performed. The pathological finding was a moderately differentiated adenocarcinoma (Gleason score 3 + 4 = 7) (Fig. 1A). The surgical margins and obturator lymph nodes were negative.
Fig. 1

A. (left), Histopathological examination shows moderately differentiated adenocarcinoma (Gleason score 3 + 4 = 7) (H & E staining, ×200). B. (right), The biopsy of the swollen inguinal lymph node shows adenocarcinoma. The tumor cell cytoplasm shows vacuolar degeneration (H & E staining, ×200).

A. (left), Histopathological examination shows moderately differentiated adenocarcinoma (Gleason score 3 + 4 = 7) (H & E staining, ×200). B. (right), The biopsy of the swollen inguinal lymph node shows adenocarcinoma. The tumor cell cytoplasm shows vacuolar degeneration (H & E staining, ×200). He was young and was a high-risk patient for recurrence; hence, postoperative adjuvant hormonal therapy (leuproreline and bicalutamide) was started immediately. Three years later, hormonal therapy was changed to monotherapy (bicalutamide). Monotherapy was discontinued because the PSA level was maintained below 0.04 ng/mL for eight years. Two years after the discontinuation, the PSA level increased gradually to 0.73 ng/ml. A CT scan showed no metastasis. He was diagnosed with biochemical recurrence and refused to receive salvage radiotherapy. Complete androgen blockade (leuproreline and bicalutamide) was restarted, and an intensive follow-up was performed every 1 to 1.5 months. Twenty-one months after the biochemical recurrence, the PSA level increased to 10.4 ng/mL and a CT scan showed left inguinal lymphadenopathy (Fig. 2A). The maximum size of the lymph nodes was 2 cm in diameter. To determine whether the lymphadenopathy was caused by metastatic prostate cancer, one of the swollen inguinal lymph nodes was obtained by open biopsy. Pathological findings revealed metastatic prostate cancer (Fig. 1B). The patient was then treated with estramustine phosphate sodium and dexamethasone for 1 year. The size of the lymph node decreased to 8 mm in diameter, and no other metastatic lesions were found (Fig. 2B). The PSA level decreased to 0.2 ng/mL.
Fig. 2

A. (top), A CT scan shows the swollen left inguinal lymph nodes with maximum size of 2cm in diameter. B. (bottom), The maximum size of the lymph nodes decreased to 8 mm in diameter due to secondary hormonal therapy.

A. (top), A CT scan shows the swollen left inguinal lymph nodes with maximum size of 2cm in diameter. B. (bottom), The maximum size of the lymph nodes decreased to 8 mm in diameter due to secondary hormonal therapy.

DISCUSSION

Thirteen years after surgery and adjuvant hormonal therapy, the prostate adenocarcinoma metastasized only to the inguinal lymph nodes in this patient. In a study by Jackson AS et al., 9% of patients with prostate cancer that had metastasized only to the lymph nodes had inguinal lymphadenopathy [2]. However, all patients also had pelvic nodal enlargement. Only two patients presenting with prostate cancer and metastasis to the inguinal lymph nodes have been reported [3, 4]. Our case is the first report in which prostate adenocarcinoma postoperatively metastasized only to the inguinal lymph nodes. In this case, pathological findings showed no lymphatic or vessel invasion and no metastasis to the obturator lymph nodes. However, metastasis to the inguinal lymph nodes occurred. There are three possible explanations for this. First, the prostate adenocarcinoma might have spread via aberrant lymphatic drainage of the prostate before the surgery. Second, a tiny focus of local residual prostate adenocarcinoma spread through uncommon routes of lymphatic drainage because of postoperative distortion of the lymphatic drainage. Many uncommon routes of lymphatic drainage have been reported, such as the periprostatic and seminal vesicle nodes, gonadal vessels, mesenteric and mesocolic nodes, posterior iliac crest nodes, and inferior phrenic nodes [4-6]. And finally, neoadjuvant hormonal therapy cuased degeneration of cancer cells and metastasis to the obturator lymph node couldn't be detected. For an early diagnosis, repeated CT scans, careful interpretation of radiograms, and a complete physical examination including palpation of the inguinal region are important. Inguinal lymphadenopathy is a manifestation of adenocarcinoma, lymphoma, leukemia, infection, cat scratch disease, sexually transmitted disease, and metastatic disease from anal, penile, urethral, and skin cancers [4, 7]. Open or needle inguinal lymph node biopsy or inguinal lymphadenectomy are essential diagnostic tools [8]. In general, open biopsy may be more invasive than needle biopsy. However, open biopsy of only one swollen lymph node might be less invasive and more ideal because the larger sample will allow for better chances of actually detecting cancer cells if they are present. In this case, we had to investigate the cause of the lymphadenopathy because prostate adenocarcinomas rarely metastasize only to the inguinal lymph nodes. Postoperative complications such as lower extremity edema did not occur. In such cases, open biopsy of the lymphadenopathy can be an effective diagnostic tool. Secondary hormonal therapy is thought to be the only choice for castration-resistant prostate cancer that metastasizes only to the inguinal lymph nodes. However, a combination of hormonal and radiation therapy or additional inguinal lymphadenectomy might have some advantages if prostate adenocarcinoma was limited in the inguinal lymph nodes. Early diagnosis and combination therapy might then be worth considering. In this case, the patient refused radiation therapy and additional lymphadenectomy, so we performed secondary hormonal therapy alone.
  8 in total

1.  Re: Carcinoma of the prostate presenting as inguinal adenopathy.

Authors:  S A Slavis; H Golji; J B Miller
Journal:  Cleve Clin J Med       Date:  1990 Jan-Feb       Impact factor: 2.321

2.  Generalized lymphadenopathy: a rare presentation of disseminated prostate cancer.

Authors:  Basak Oyan; Huseyin Engin; Suayib Yalcin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

3.  Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer.

Authors:  P S Kothari; P T Scardino; M Ohori; M W Kattan; T M Wheeler
Journal:  Am J Surg Pathol       Date:  2001-11       Impact factor: 6.394

4.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

5.  Prostate adenocarcinoma presenting with inguinal lymphadenopathy.

Authors:  Eugene Huang; Bin S Teh; Dina R Mody; L Steven Carpenter; E Brian Butler
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

6.  Pathways of nodal metastasis from pelvic tumors: CT demonstration.

Authors:  J M Park; C Charnsangavej; K Yoshimitsu; D H Herron; T J Robinson; S Wallace
Journal:  Radiographics       Date:  1994-11       Impact factor: 5.333

7.  Fine needle aspiration biopsy diagnosis of metastatic prostate carcinoma to inguinal lymph node.

Authors:  Marilin Rosa; Harpreet K Chopra; Sunati Sahoo
Journal:  Diagn Cytopathol       Date:  2007-09       Impact factor: 1.582

8.  Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy.

Authors:  A S N Jackson; S A Sohaib; J N Staffurth; R A Huddart; C C Parker; A Horwich; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-03       Impact factor: 4.126

  8 in total
  4 in total

1.  Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.

Authors:  Kilian Schiller; K Sauter; S Dewes; M Eiber; T Maurer; J Gschwend; S E Combs; G Habl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-23       Impact factor: 9.236

2.  Prostatic adenocarcinoma presenting as isolated inguinal lymphadenopathy.

Authors:  Kanakaiah Doreswamy; Vilvapathy Senguttuvan Karthikeyan; Mahadevappa Nagabhushana; Bharatnur Shankaranand
Journal:  BMJ Case Rep       Date:  2015-07-07

3.  AIRE promotes androgen-independent prostate cancer by directly regulating IL-6 and modulating tumor microenvironment.

Authors:  Rashi Kalra; Ella Bhagyaraj; Drishti Tiwari; Ravikanth Nanduri; Anuja P Chacko; Monika Jain; Sahil Mahajan; Neeraj Khatri; Pawan Gupta
Journal:  Oncogenesis       Date:  2018-05-25       Impact factor: 7.485

Review 4.  Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature.

Authors:  Marialuisa Appetecchia; Agnese Barnabei; Vincenzo Pompeo; Steno Sentinelli; Roberto Baldelli; Salvatore Maria Corsello; Francesco Torino
Journal:  BMC Endocr Disord       Date:  2014-10-11       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.